Alex Wyatt: Will ctDNA serve as a treatment response biomarker in metastatic cancers

Alex Wyatt, Associate Professor at Vancouver Prostate Centre, shared a post on X about a recent paper published in Clinical Cancer Research.

“Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group “

Authors: Alexander Wyatt, Saskia Litière, Francois-Clement Bidard, Scott Laurie, Elena Garralda et al.

“Will ctDNA serve as a treatment response biomarker in metastatic cancers?

Here’s a thorough evaluation in Clinical Cancer Research from the RECIST working group, looking at the next steps towards using ctDNA for novel early endpoints in clinical trials and beyond.”

Daniel Stover, Vice Chair of Alliance for Clinical Trials in Oncology, shared this post, adding:

“Imaging has limitations. ctDNA has limitations. Can the two together overcome the distinct limitations?

Very excited about some upcoming data from several studies Daniel Stover is doing with Foundation Medicine and, separately Broad Institute!”

Source: Alex Wyatt/X and Daniel Stover/X